Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Cenobamate efficacy occurs early during titration

Bernhard Steinhoff, MD, PhD, Kork Epilepsy Center, Kehl-Kork, Germany, shares the findings of an investigation of time to onset of efficacy of cenobamate as an adjunctive therapy in adults with uncontrolled focal seizures. The post-hoc analysis assessed time to onset of efficacy during titration in participants of two randomized placebo-controlled trials of cenobamate (C013, NCT01397968; C017, NCT01866111). The results demonstrated a significant decrease in seizure frequency with cenobamate compared to placebo throughout the 6-week titration in both studies. Onset of cenobamate efficacy occurred early during titration and continued to improve at higher doses. Additionally, efficacy was seen at lower doses than the targeted dose for maintenance therapy. his interview took place during the European Academy of Neurology 2021 congress.


Prof. Steinhoff reports the following disclosures:
Paid consultant/advisor/lecturer: Arvelle, B. Braun Melsungen, Desitin, Eisai, GW Pharmaceuticals, Neuraxpharm, UCB and Zogenix
Research support: Eisai, GW Pharmaceuticals, Precisis, SK Life Science, UCB, and Zogenix.